Next-generation sequencing market is driven by technological development in next-generation sequencing, increase in the various applications, decreasing the cost of sequencing, increase in gene mapping programs, increasing automation for pre-sequencing programs, and development of personalized medicine which are expected to fuel the next generation sequencing market. Moreover, rise in R&D activities by the market players and drug discovery applications are driving the demand for next-generation sequencing (NGS) market. However, lack of skilled professionals, ethical and legal issues in the interpretation, storage and management of patient data, and high reliability on funding from the government might hamper the next generation sequencing market over the forecast period.
A sample of this report is available upon request @
The next generation sequencing market segmented based on the product and service type, technology, application type, and end user
Based on the product and service type, the next-generation sequencing market segmented into the following:
Pre-sequencing products and services market
DNA fragmentation, size selection, A-tailing, and end repair
Library preparation and target enrichment
Sequencing services market
Targeted sequencing/gene panels
De Novo sequencing
Next-generationn sequencing, data analysis, storage, and management (Bioinformatics) market
NGS data analysis software & workbenches
NGS data analysis services
NGS storage management and cloud computing solutions
Based on technology, the next-generation sequencing market segmented into the following:
Ion semiconductor sequencing
Sequencing by the synthesis (SBS)
Single-molecule real-time (SMRT) sequencing
Based on application, the next-generation sequencing market segmented into the following:
Agriculture and animal research
Based on the end-user, the next-generation sequencing market segmented into the following:
Biotechnology and Pharmaceutical Companies
Hospitals & Clinics
To view TOC of this report is available upon request @
The global next-generation sequencing market is in growing stage, several local and international players are actively involved in the development and marketing of global next-generation sequencing market. Organizations are focusing on the introduction of low-cost sequencing devices in routine medical check-ups. For instance, Grail is focusing on the development of a next generation sequencing technology that allows detection of different types of cancer before the symptoms appear. This test is expected to reach the market by 2019. Furthermore, companies are also engaged in producing genomic data by making it available to research laboratories worldwide. Growing partnerships, collaborations, increasing adoption of NGS among research laboratories and academic institutes, and the launch of services and novel products by market players fuel the growth of global next generation sequencing market over the forecast period. Moreover, increase in inclination of drug developers and scientists towards the next generation sequencing technology for the development of personalized medicine is a key driver for the demand of next generation sequencing platforms for gaining insights into the genetic organization.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/global-next-generation-sequencing-market/#ulp-14mlyhjMGhVjZqa3
Next-generation sequencing market segmented into following regions Viz. North America, Asia-Pacific, Latin America, Europe, and Middle East and Africa. North America expected to hold a major share, which is attributed to rise in adoption of next generation sequence, development in the healthcare infrastructure, decrease in the cost, and increase in the R&D activities for proteomic and genomic sequence determination. Moreover, most of the end users for clinical and academic use are from the U.S., U.K., and Germany due to presence of universities offering molecular biology course in these regions might bolster the next generation sequencing market. For instance, in June 2015, Illumina has opened its Europe headquarters in the Cambridge to increase its revenue through 10,000 genome project carried out in U.K. Asia-Pacific is expected to grow at the fastest rate in global next generation sequencing market with owing to increasing investment in development in healthcare expenditure, rising medical awareness in regional population, government funding for translational research, and rising partnerships & agreements among market players. In addition, these countries have less-stringent regulations and data requirements as compared to developed nations; companies find regulatory policies in the Asia-Pacific region to be adaptive and business-friendly.
Get access to full summary @
Some of the players in global next-generation sequencing market are Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Pacific Biosciences (Danaher Corporation) (U.S.), Thermo Fisher Scientific Inc. (U.S.), Qiagen N. V. (Germany), Beijing Genomics Institute (China), PerkinElmer, Inc (U.S.), F. Hoffmann La Roche AG (Switzerland), Genomatix GmbH (Germany), Oxford Nanopore Technologies (U.K.), and Eurofins Scientific (U.S.) to name a few.